<DOC>
	<DOCNO>NCT02771301</DOCNO>
	<brief_summary>This trial aim evaluate safety efficacy IDH1R132H-DC vaccine glioma IDH1R132H mutation .</brief_summary>
	<brief_title>Safety Efficacy IDH1R132H-DC Vaccine Gliomas</brief_title>
	<detailed_description>Eligible patient provide write informed consent undergo apheresis collect blood mononuclear cell vaccine production . All patient receive mature dendritic cell total 12 vaccine doses.The DC vaccine give subcutaneously every four week . Peripheral blood take two week injection time monitor immune response .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>The patient sign `` informed consent '' voluntarily ; The age patient 18 70 year ; The tumor resect tumor resection rate ≥80 % ; IDH1R132H mutation confirm immunohistochemistry realtime quantitative PCR ; Peripheral blood lymphocyte absolute value le 0.8 × 106 ; KPS score ≥70 ; The patient normal bone marrow reserve normal liver kidney function ( The bone marrow , liver kidney function must confirm Laboratory examination meet requirement participate study within 3 day first acceptance IDH1R132HDC tumor vaccine therapy ) : Medium neutrophil absolute value ≥1,500 / mm3 ; hemoglobin &gt; 10g / dL ; platelet count &gt; 100,000 / mm3 ; total bilirubin &lt; 1.5 × ULN ; alanine aminotransferase / aspartate aminotransferase &lt; 2.5 × ULN ; serum creatinine &lt; 1.5 × ULN ; Normal heart function ; Better followup compliance ; For woman childbearing age ( 15 49 year ) ，pregnancy test must negative 7 day start study . Male female patient childbearing potential must agree use effective contraceptive measure ensure study period three month cessation treatment pregnant . The patient sign `` informed consent '' sign unvoluntarily . Nonglioma patient Drugs brain antibody therapy use 4 week start study Active infection Human immunodeficiency virus ( HIV ) positive Hepatitis C hepatitis B infective Pregnancy breastfeed woman Patients agree use effective contraception treatment follow 3 month . Patients also participate clinical study . The subject researcher believe suitable participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>IDH1R132H Dendritic cell glioma</keyword>
</DOC>